Current stock page

Stock Analysis

Arcus Biosciences, Inc. (RCUS) Stock Analysis

Arcus Biosciences, Inc. (RCUS) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

RCUS Stock Analysis Summary

Arcus Biosciences, Inc. (RCUS) currently has an AIQ Score of 39/100, indicating a bearish setup. Value is the strongest factor at 43/100. Momentum is the weakest current factor at 34/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

RCUS at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$17.43
AIQ Score39/100
Overall ViewBearish
Technical Analysis ConsensusStrong Sell
Market Cap$2.22B
P/E Ratio (TTM)-4.76
Forward P/E—
EPS (Q3 FY2026)-$1.00
Revenue (Q3 FY2026)$9M
Dividend Yield (TTM)0.00%
Beta1.56
Volume1.14M
52-week range$17.03-$31.74
RSI 1435.06
50-Day SMA$22.62
200-Day SMA$24.47
Analyst Price Target$45.50
Next EarningsFeb 24, 2027
As of Nov 13, 2026 · Market close

RCUSArcus Biosciences, Inc.

Healthcare / Biotechnology

Low Priority

Relative Laggard

BearishEdge 2/10
$17.43−$0.34 (−1.91%)

Latest quote

  • Momentum
    34
  • Value
    43
  • Quality
    41
  • Risk resilience
    42
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

RCUS Stock Analysis Summary

Arcus Biosciences, Inc. (RCUS) currently has an AIQ Score of 39/100, indicating a bearish setup. Value is the strongest factor at 43/100. Momentum is the weakest current factor at 34/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Bearish

In a bearish regime, RCUS has AIQ Score of 39/100 with Value base of 43/100 and fading Momentum at 34/100. Wait for component alignment before adding exposure.

Healthcare · -1.91% stock move · RCUS classified in Biotechnology.

Current Evidence

BearishRCUS is in a bearish AIQ regime; Value is the strongest visible factor at 43/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is RCUS Bullish or Bearish Right Now?

RCUS currently has a bearish overall setup. Value is the strongest factor at 43/100, while Momentum is weakest at 34/100. The current evidence suggests a bearish setup.

Bull Case
  • - Analyst target implies +161.04% upside from the latest quote.
Bear Case
  • - Value is the current constraint at 43/100.
  • - Momentum is weak at 34/100.
  • - Risk Resilience is weak at 42/100.
  • - Price is -28.77% below its 200-day SMA.
  • - Technical consensus has more sell votes than buy votes (34 vs 7).

Current Consensus

RCUS's Technical Analysis Consensus is currently Strong Sell, with 7 buy, 5 neutral, and 34 sell votes. RCUS's 14-day RSI is 35.06, which places the stock in a weaker momentum range. RCUS's beta is 1.56, indicating greater market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in RCUS?

The largest recent change in RCUS is Value moving up by 3.0 points over the available 7-day comparison window. Value remains the strongest visible factor.

AIQ Score
+1.0
Momentum
+0.0
Quality
+1.0
Risk
+0.0

What Would Change the RCUS Outlook?

The current bearish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

RCUS Decision Framework

Public evidence layers, setup checks, and risk context for Arcus Biosciences, Inc..

Arcus Biosciences, Inc. (RCUS) Stock Analysis

Arcus Biosciences, Inc. has an AIQ Score of 39/100 in a Bearish regime. Value is strongest at 43/100. Beta is 1.56, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextRCUS is in a Bearish AIQ regime with score 39/100.
Signal ConflictThe primary conflict is that value leads at 43/100 while momentum lags at 34/100.
Factor EvidenceMomentum 34/100 · Value 43/100 · Quality 41/100 · Risk 42/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthFail

Value is the strongest factor at 43/100.

TimingFail

Momentum is 34/100 and RSI (14) is 35.1.

Regime fitFail

RCUS is in a Bearish regime at 39/100.

Risk controlFail

Risk factor is 42/100 with beta 1.56 and annual volatility 62.65%.

ConflictPass

Current conflict: value leads at 43/100 while momentum lags at 34/100.

AIQ Score
39/100
Price
$17.43
Beta
1.56
RSI (14)
35.1

RCUS Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

RCUS Fundamentals

RCUS valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$9M
Net income
-$128M
Free cash flow
-$88M
View full RCUS fundamental analysis

RCUS Technical Analysis

RCUS technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Sell
RSI 14
35.06
Price vs SMA-50
-22.94%
View full RCUS technical analysis

RCUS Stock Catalysts

Track RCUS earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Feb 24, 2027
Analyst target
$45.50
News items
5
View RCUS earnings and stock catalysts

RCUS Dividend Analysis

RCUS dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View RCUS dividend history and analysis

RCUS Financial Data

RCUS revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$9M
EPS
-$1.00
Periods
8
View RCUS financials

RCUS Risk Analysis

RCUS volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
1.56
Risk score
42/100
1Y volatility
62.65%
View RCUS risk analysis

RCUS Stock News

RCUS stock news, market tone, recent headlines, and catalyst context.

News items
5
Updated
Nov 15, 2026
Sentiment
—
Read RCUS stock news

RCUS vs Biotechnology Peers

Current peer cohort: RCUS · REPL · RLAY · RVMD · RYTM. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
RCUS
Current stock
39/10043/10034/10042/1000.0562.65%Current
REPL
Replimune Group, Inc.
60/100—97/10026/1001.3187.93%RCUS vs REPL
RLAY
Relay Therapeutics, Inc.
56/10037/10076/10052/1001.8465.80%RCUS vs RLAY
RVMD
Revolution Medicines, Inc.
55/10039/10073/10059/1001.6968.69%RCUS vs RVMD
RYTM
Rhythm Pharmaceuticals, Inc.
62/10052/10072/10057/1000.5254.57%RCUS vs RYTM
Pairwise Compare links: REPL · RLAY · RVMD · RYTMRCUS vs REPLRCUS vs RLAYRCUS vs RVMDRCUS vs RYTMCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a RCUS stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for RCUS: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-4.76
As of Nov 13, 2026
Revenue growth
-65.38%
Gross margin
95.00%
Current debt / equity
0.32
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$9M
Quarter net income
-$128M
Quarter free cash flow
-$88M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Bearish
Momentum
Mixed
RSI 14
35.06
MACD
-1.38

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
42/100
Beta
1.56
Annual volatility
62.65%
Max drawdown
-44.79%

RCUS Stock FAQ

What is RCUS stock price today?

Arcus Biosciences, Inc.'s current stock price is $17.43. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is RCUS bullish or bearish right now?

RCUS's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is RCUS's market cap?

RCUS's market cap is $2.22B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is RCUS's current P/E ratio?

RCUS's current P/E ratio is -4.76 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is RCUS's RSI?

RCUS's 14-day RSI is 35.06 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is RCUS above its 50-day and 200-day moving averages?

RCUS is -22.94% from its 50-day SMA and -28.77% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is RCUS's next earnings date?

RCUS's next earnings date is currently listed as Feb 24, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does RCUS pay a dividend?

RCUS's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.